Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
NCT04703842
This study is recruiting at 5 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
It is believed that targeted SERCA2a enzyme replacement in HFrEF patients will correct defective intracellular Ca2+ hemostasis, resulting in improved cardiac contractile function and energetics which will, in turn, translate to improved clinical outcomes. Additionally, it is hypothesized that correcting SERCA2a dysfunction will also improve coronary blood flow through correction of the impaired endothelium-dependent nitric oxide-mediated vasodilatation observed in heart failure.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Congestive Heart Failure
- Heart Failure, Systolic
- Heart Failure
- HFrEF - Heart Failure With Reduced Ejection Fraction
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Sardocor Corp.
- Last updated on ClinicalTrials.gov
- March 26, 2024
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 2
- San Diego Cardiac Center · San Diego, CA
- University of California, San Francisco · San Francisco, CA
Missouri · 1
- Washington University in Saint Louis · St Louis, MO
Texas · 1
- University of Texas Southwestern Medical Center · Dallas, TX
Washington · 1
- University of Washington Medicine · Seattle, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.